Navigation Links
Prolexys Pharmaceuticals Initiates Phase 1 Study
Date:8/29/2007

Novel Agent Administered in First-In-Human Study to Cancer Patients

SALT LAKE CITY, Aug. 29 /PRNewswire/ -- Prolexys Pharmaceuticals, Inc. today announced that its first-in-humans Phase 1 study of PRLX 93936 has begun. This open-label trial is designed to evaluate the safety, pharmacokinetic and pharmacodynamic properties of PRLX 93936 in patients with advanced solid tumors. Study sites include TGen Clinical Research at Scottsdale Healthcare in Scottsdale, Arizona, and Tower Cancer Research Foundation in Beverly Hills, California. The first Phase 1 study will be a dose-escalating trial involving up to 36 patients.

"We are enthusiastic about our participation in the study of this interesting new agent with what appears to be a unique mechanism of action," said Dr. Daniel Von Hoff, Physician-in-Chief and Director of Clinical Research at TGen, and the principal investigator for the study at Scottsdale Healthcare. "Rarely have we seen pre-clinical anti-tumor effects that match those produced by PRLX 93936. We're very hopeful that this compound will have a therapeutic effect in patients with tumors that are non-responsive to existing therapeutic agents."

"The initiation of this Phase I clinical trial demonstrates our commitment to develop novel approaches to cancer therapies based on the company's proteomics technology platform," said David Clark, President and CEO of Prolexys.

"Based on the broad anti-cancer activity we have seen in pre-clinical models, we are looking forward to evaluating the potential anti-cancer activity in humans for this new drug candidate," stated Dr. Sudhir Sahasrabudhe, Prolexys' Chief Scientific Officer.

About PRLX 93936

PRLX 93936 is a structural analog of a compound called erastin, in-licensed by Prolexys from the MIT/ Whitehead Institute in January 2005. Erastin was identified as a potential anti-cancer therapeutic in a screen against cell lines engineered to differentially express several oncogene
'/>"/>

SOURCE Prolexys Pharmaceuticals, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2

Related medicine technology :

1. Prolexys Pharmaceuticals and Columbia University Researchers Publish Study on Anti-Tumor Properties of a Selective Small Molecule Anti-Tumor Agent With Novel Mechanism of Action
2. Inspiration Biopharmaceuticals Presents Data From Hemophilia Program at International Society On Thrombosis and Haemostasis (ISTH) Annual Meeting
3. BioSante Pharmaceuticals Announces New Findings for Potential Bird Flu Vaccine
4. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
5. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
6. Auxilium Pharmaceuticals to Present at the 2007 CEUT Emerging Growth Opportunities Conference
7. Sunesis Pharmaceuticals to Present at the C. E. Unterberg, Towbin Emerging Growth Conference
8. EPIX Pharmaceuticals to Present at the C.E. Unterberg, Towbin Emerging Growth Opportunities Conference
9. Pro-Pharmaceuticals Updates Progress of Clinical Trials & Davanat 505 (b)(2) Filings
10. Cosmo Pharmaceuticals Reports Positive Preliminary Phase II/III Data with Rifamycin MMX in Infectious Diarrhea
11. Portola Pharmaceuticals Announces Positive Phase II EXPERT Results and Additional Oral and Poster Presentations at the XXI Congress of the International Society on Thrombosis and Haemostasis (ISTH)
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... TORONTO , Jan. 15, 2014  According ... on medical technology market intelligence, the ... and occlusion (TEO) device markets will expand moderately ... the fastest-growing segments. In particular, increasing interest in ... oncology has fueled rapid growth of these markets. ...
(Date:1/15/2014)... , Jan. 15, 2014 ... report is available in its catalogue: ... India Drug Forecast and Market Analysis to ... PharmaPoint: Atopic Dermatitis - India Drug ... Summary,Although the past decade has seen ...
(Date:1/15/2014)... YORK , Jan. 15, 2014 /PRNewswire/ ... research report is available in its catalogue: ... Technologies for Advanced Drug Delivery Systems -- ... http://www.reportlinker.com/p01940411/Global-Markets-and-Technologies-for-Advanced-Drug-Delivery-Systems----Focus-on-End-Users.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=Drug_Delivery_Technology STUDY OBJECTIVES ... of the very important aspects in today,s ...
Breaking Medicine Technology:US and European Transcatheter Embolization and Occlusion Device Market to Surpass $1.6 Billion by 2022 2US and European Transcatheter Embolization and Occlusion Device Market to Surpass $1.6 Billion by 2022 3PharmaPoint: Atopic Dermatitis - India Drug Forecast and Market Analysis to 2022 2PharmaPoint: Atopic Dermatitis - India Drug Forecast and Market Analysis to 2022 3PharmaPoint: Atopic Dermatitis - India Drug Forecast and Market Analysis to 2022 4PharmaPoint: Atopic Dermatitis - India Drug Forecast and Market Analysis to 2022 5Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 2Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 3Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 4Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 5Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 6Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 7Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 8Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 9Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 10Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 11Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 12Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 13Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 14Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 15Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 16Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 17Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 18
... 2011 Landauer, Inc. (NYSE: LDR ... of 2011 pre-market on Tuesday, February 1, 2011. ... Tuesday, February 1, 2011, at 2:00 p.m. Eastern Time. Investors ... United States and Canada), or 480-629-9726 (international callers), or by ...
... CVS Caremark Corporation (NYSE: CVS ) will ... 2011, at 8:30 a.m. (ET) with analysts and investors ... well as its initial guidance for 2011. ... conference call will be broadcast simultaneously through the Investor ...
Cached Medicine Technology:Landauer, Inc. Sets Date and Time for Announcement of Fiscal First Quarter 2011 Results 2
(Date:4/14/2014)... Popular web information on colorectal cancer is too ... address the appropriate risks to and concerns of patients, ... , In a review of a dozen popular websites, ... cancer screening were written beyond the recommended sixth-grade reading ... key risks, as well as the barriers to and ...
(Date:4/14/2014)... Scientists found that the molecule, called microRNA 135b, is ... to drive the growth of bowel cancers. , Drugs ... of multiple cancer-causing mutations at once, while tests for ... the researchers believe. , The research was carried out ... Institute of Cancer Research, London, the University of Glasgow ...
(Date:4/14/2014)... SAN FRANCISCO, Calif.--True North Therapeutics, Inc., announced today ... prevents the destruction of human red blood cells ... type of autoimmune hemolytic anemia (AIHA). The article ... C1s, prevents complement activation induced by cold agglutinin ... journal Blood earlier this month. TNT003 ...
(Date:4/14/2014)... have unearthed still more evidence that antibiotics can ... print in the journal Antimicrobial Agents and ... treatment gained weight and had significant changes in ... by Didier Raoult, of Aix-Marseille University, Marseille, France, ... with doxycycline and hydroxychloroquine for Q fever, and ...
(Date:4/14/2014)... Porter Graham Child Development Institute have released their ... to prepare four-year-olds for success in kindergarten. According ... show significant gains across all areas of learning. ... greater rate during their participation in NC Pre-K ... scientist Ellen Peisner-Feinberg, who leads the FPG team ...
Breaking Medicine News(10 mins):Health News:Website information on colon cancer too complex, fails to address key concerns 2Health News:Website information on colon cancer too complex, fails to address key concerns 3Health News:'MicroRNA' could be key target for bowel cancer treatment 2Health News:Ex vivo efficacy of C1s antibody as Complement inhibitor in cold agglutinin disease 2Health News:Long-term antibiotic treatment for Q fever causes weight gain 2Health News:Study gives high marks to NC Pre-K program 2
... to Accelerate Sales of the New, Fully Nano-Encapsulated Liquid Vitamin, ... and COLUMBUS, Ohio, June 23 livethesource(TM) announced ... has joined the company,s distribution network to help ... its breakthrough technology, daily source(TM) is a complete ...
... suggests a direct link between smoking and brain damage will ... of Neurochemistry . Researchers, led by Debapriya Ghosh and Dr ... have found that a compound in tobacco provokes white blood ... leading to severe neurological damage. The research centers ...
... Each year hospital operating rooms face increasingly difficult ... more demanding. Saint Vincent Health Center (SVHC) in ... provided by Eclipsys Corp. and powered by Surgical Information ... and national averages for quality measures. , , ...
... Derma Sciences, Inc. (OTC ... products, announced today that it has begun shipping BIOGUARD(TM) ... that it has been awarded reimbursement codes for the ... BIOGUARD will offer surgeons, wound care clinicians, infection ...
... WASHINGTON, June 23 A study released earlier this month ... Ohio University found that medical bills are involved ... 50 percent just six years ago. Additionally, more than 75 ... overwhelmed by the out-of-pocket expenses. In the wake of these ...
... Center offers more services to autistic community with the help ... Judson Center ( www.judsoncenter.org ), a comprehensive ... of individuals and families, today opens the newly-constructed Autism Center ... headquarters. Judson Center employees, autism advocates and families as ...
Cached Medicine News:Health News:Internationally-Renowned Health and Wellness Authority Joins livethesource(TM) as a Master Distributor 2Health News:Internationally-Renowned Health and Wellness Authority Joins livethesource(TM) as a Master Distributor 3Health News:New research discovers link between smoking and brain damage 2Health News:Saint Vincent Health Center Ensures Regulatory Compliance with SIS 2Health News:Saint Vincent Health Center Ensures Regulatory Compliance with SIS 3Health News:Derma Sciences Announces First Commercial Sales of BIOGUARD(TM) Barrier Dressings 2Health News:Derma Sciences Announces First Commercial Sales of BIOGUARD(TM) Barrier Dressings 3Health News:Derma Sciences Announces First Commercial Sales of BIOGUARD(TM) Barrier Dressings 4Health News:The Wellness Community Launches National Education Program Addressing the Cost of Cancer Care 2Health News:The Wellness Community Launches National Education Program Addressing the Cost of Cancer Care 3Health News:Judson Center Celebrates Grand Opening of its New Autism Center 2
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
Medicine Products: